Skip to main content
Back to Top

 

Chin Hur, MD, MPH

Credentials

Assistant Professor in Medicine, Harvard Medical SchoolDirector, GI Health Outcomes Research, Massachusetts General HospitaCoordinating Principal Investigator, CISNET Esophagus Cancer Group

Biography

Dr. Chin Hur is the coordinating Principal Investigator for the CISNET Esophagus Cancer Group. In conjunction with his role in CISNET, Dr. Hur is the Director of Gastrointestinal (GI) Health Outcomes Research at Massachusetts General Hospital, Institute for Technology Assessment and GI Unit and on the faculty of Harvard Medical School in Boston, Massachusetts. Dr. Hur is a practicing gastroenterologist who specializes in Barrett’s esophagus and esophageal cancer. His health outcomes research focuses on screening and the management of gastrointestinal malignancies and their precursors (e.g. dysplastic states).  CISNET Esophagus Cancer GroupThe Esophagus Cancer group is a new addition to NCI’s CISNET program Cancer groups, a recent expansion to include esophageal cancer as one of the targeted cancers within its network. Funding for the Esophagus Cancer group started in September 2010. As a new cancer group, the group has the distinctive opportunity to perform groundbreaking analyses and provide crucial evidence syntheses that are urgently needed and novel. The cancer group has already “developed agreed upon calibration targets to begin our base case analyses which is the first and crucial step in developing and assessing a natural history model of esophageal adenocarcinoma” according to Dr. Hur.The incidence of esophageal adenocarcinoma (EAC) has been rising at an alarming rate over the past three decades.  Although the absolute number of EAC cases per year remains too low to screen the general population, targeted screening may be appropriate.  Heartburn, the primary symptom of gastroesophageal reflux disease (GERD), affects 60 million Americans and can lead to Barrett’s esophagus (BE), a pre-malignant condition associated with the greatest risk (30-125x) of developing EAC.  Because of the significant number of individuals affected with GERD and BE, the management of these patients has become a public health issue.  However, an accepted screening or surveillance program for EAC has not been proposed.The ultimate goal of the CISNET Esophagus Cancer group is to advance understanding of esophageal cancer and the impact of cancer control interventions in order to diminish the burden of this disease through the use of collaborative and comparative modeling. The research conducted by the group will address the overarching goals of increasing our understanding of the natural history of esophageal cancer and determining potential impact of cancer control interventions, with the ultimate goal of ameliorating cancer morbidity. The Esophagus Cancer group will work to bring together different simulation models and embrace differences in model structures to improve the overall understanding of a cancer’s natural history and improve model projections. According to Dr. Hur, “Our innovative collaboration will perform comparative modeling that focuses on, but is not limited to, determining the effectiveness of clinically relevant issues in esophageal cancer, multiscale modeling and incorporation of biomarkers, and the creation and dissemination of an interactive policy level decision tool.” Dr. Hur went on to state that, “We are enthusiastically committed to the project and strongly believe that with the team assembled we have the opportunity to make significant contributions.”Recent publications Hur C, Hayeck TJ, Yeh JM, Richards EB, Spechler SJ, Gazelle GS, Kong CY.  Development, Calibration, and Validation of a U.S. White Male Population-based Simulation Model of Esophageal Adenocarcinoma. PLoS ONE 2010;5(3):e9483.Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C.  The Prevalence of Barrett’s Esophagus in the US: Estimates from a Simulation Model Confirmed by SEER Data. Dis Esophagus 2010 [Epub March 26].Yeh JM*, Hur C, Kuntz KM, Ezzati M, Goldie SJ.  Cost-effectiveness of Treatment and Routine Surveillance of Precancerous Lesions to Prevent Gastric Cancer. Cancer 2010 Jun 15;116(12):2941-53.Hur C, Broughton DE, Ozanne E, Nishioka NS, Gazelle GS.  Patient Preferences for Chemoprevention in Barrett’s Esophagus. Am J of Gastro 2008;103(10):2432-2442.Hur C, Nishioka N, Gazelle GS.  Cost-effectiveness of Aspirin Chemoprevention for Barrett's esophagus. Journal of the National Cancer Institute 2004;96(4):316-25.